Growth in biofilms as a fascinating and complex microbial lifestyle has become widely accepted as one of the key features of pathogenic microbes, to successfully express their full virulence potential and environmental persistence. This also increases the threat posed by , which has a high intrinsic ability to persist on abiotic surfaces including those of surgical instruments and medical tubing. In a previous study, cyclic and helical-stabilized analogues of the antifungal peptide Cm-p5 were designed and synthetized, and proved to have increased activities against and , but not against planktonic cells cultivated in suspension cultures. Here, we demonstrate, initially, that these derivatives, however, exhibited semi-inhibitory concentrations between 10-21 µg/mL toward biofilms. Maturated biofilms were also arrested between 71-97%. These novel biofilm inhibitors may open urgently needed new routes for the development of novel drugs and treatments for the next stage of fight against .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400495PMC
http://dx.doi.org/10.3390/antibiotics9070363DOI Listing

Publication Analysis

Top Keywords

antifungal peptide
8
peptide cm-p5
8
derivates antifungal
4
cm-p5 inhibit
4
inhibit development
4
biofilms
4
development biofilms
4
biofilms vitro
4
vitro growth
4
growth biofilms
4

Similar Publications

Scorpion venom is a highly complicated cocktail of bioactive components including mucoproteins, enzymes, lipids, bioactive peptides, and other organic or inorganic molecules. Scorpion venom antimicrobial peptides are a class of small-molecule bioactive peptides extracted from scorpion venoms, which have shown a variety of biological activities, including antiviral, antibacterial, antifungal and antitumor actions. This review describes the progress of researches on the antiparasitic activities of scorpion venoms and their antimicrobial peptides, so as to provide insights into the research and development of novel antiparasitic agents.

View Article and Find Full Text PDF

The cardiometabolic safety of dupilumab in atopic dermatitis: A global large-scale cohort study.

Arch Dermatol Res

January 2025

Lűbeck Institute of Experimental Dermatology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.

Background: A low risk of cardiovascular and metabolic outcomes was found in the randomized clinical trials of dupilumab in atopic dermatitis (AD). Dupilumab-associated real-life long-term cardiometabolic risk relative to other systemic agents is yet to be precisely investigated.

Objective: To assess the risk of cardiometabolic outcomes in patients with AD treated with dupilumab relative to those treated with methotrexate and cyclosporine.

View Article and Find Full Text PDF

Metabolic engineering of for high-level production of pneumocandin B.

Synth Syst Biotechnol

June 2025

Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education and School of Pharmaceutical Sciences, Wuhan University, 430072, Wuhan, China.

Pneumocandin B (PB) is a lipohexapeptide synthesized by and serves as the precursor for the widely used antifungal drug caspofungin acetate (Cancidas®). However, the low titer of PB results in fermentation and purification costs during caspofungin production, limiting its widespread clinical application. Here, we engineered an efficient PB-producing strain of by systems metabolic engineering strategies, including multi-omics analysis and multilevel metabolic engineering.

View Article and Find Full Text PDF

Background: Systemic lupus erythematosus (SLE) is a complex and incurable autoimmune disease, so several drug remission for SLE symptoms have been developed and used at present. However, treatment varies by patient and disease activity, and existing medications for SLE were far from satisfactory. Novel drug targets to be found for SLE therapy are still needed.

View Article and Find Full Text PDF

Objectives: To explore the mechanism by which histone deacetylase 1 (HDAC1) regulates steroid-induced apoptosis of mouse osteocyte-like MLO-Y4 cells.

Methods: MLY-O4 cells were treated with 400 nmol/L trichostatin A (TSA) or 1 mmol/L dexamethasone for 24 h or transfected with a HDAC1-overexpressing vector prior to TSA or dexamethasone treatment. The changes in the expressions of HDAC1, SP1, cleaved caspase-3 and Bax, SP1 acetylation level, cell proliferation, and cell apoptosis were examined.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!